PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: KDM Communications Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Pro-Lab Diagnostics Launches Prolisa™ Cryptosporidium/Giardia Enzyme Immunoassay - Pro-Lab Diagnostics has developed a new enzyme immunoassay (EIA) for the qualitative detection of Cryptosporidium and Giardia lamblia antigens in human faecal specimens from patients displaying gastrointestinal symptoms - Pro-Lab.com
Pro-Lab Diagnostics Launches Prolisa™ Cryptosporidium/Giardia Enzyme Immunoassay

 

NewswireToday - /newswire/ - St Neots, Cambridgeshire, United Kingdom, 2012/02/24 - Pro-Lab Diagnostics has developed a new enzyme immunoassay (EIA) for the qualitative detection of Cryptosporidium and Giardia lamblia antigens in human faecal specimens from patients displaying gastrointestinal symptoms - Pro-Lab.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Prolisa™ Cryptosporidium/Giardia EIA kit offers precise results with high sensitivity and excellent specificity, enabling accurate diagnosis of infection.

Cryptosporidiosis is routinely diagnosed by microscopic analysis of stool samples using organic dyes or by immunostaining by direct fluorescent antibody, and can be difficult to detect. Similarly, Giardia infection is frequently misdiagnosed, relying on poorly performing antigen-based testing. Pro-Lab Diagnostics’ Prolisa™ Cryptosporidium/Giardia EIA is a convenient, rapid and easy-to-use method of detecting Cryptosporidium and G. lamblia. Supplied in a 96-well test size consisting of detachable stripwells, this manual assay uses monoclonal anti-Cryptosporidium and anti- G. lamblia antibodies to ensure excellent sensitivity and specificity for high value diagnostic results, and can also be performed on most automated platforms for increased workflow flexibility. Mark Reed, General Manager of Pro-Lab Diagnostics, commented: “The launch of the Cryptosporidium/Giardia EIA further extends the Prolisa product range, offering our customers a simple and cost-effective alternative means of testing for Cryptosporidiosis and Giardiasis with the back-up support of our team of application experts.”

About Pro-Lab Diagnostics

The Pro-Lab Group of companies (pro-lab.com) is dedicated to the provision of high quality, cost effective immunodiagnostic products and biological reagents to hospitals, private medical laboratories, veterinary laboratories, and other biological investigative laboratories. Pro-Lab Diagnostics is a privately held corporation founded in 1974 with its head office in Toronto, Canada and subsidiaries in the U.K. and U.S.A.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: KDM Communications Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pro-Lab Diagnostics Launches Prolisa™ Cryptosporidium/Giardia Enzyme Immunoassay

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sophie Woodward - KDM-Communications.com 
+44(0)15 1353 1613 uksupport[.]pro-lab.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any KDM Communications Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From KDM Communications Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  1Click Games





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)